522 related articles for article (PubMed ID: 11315605)
1. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
2. A comparison of targetting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; Kraker Jd; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 24623005
[TBL] [Abstract][Full Text] [Related]
3. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
4. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
5. The role of 99Tcm-sestamibi scintigraphy in the staging and prediction of the therapeutic response of stage IV neuroblastoma: comparison with 131I-MIBG and 99Tcm-MDP scintigraphy.
Burak Z; Yüksel DA; Cetingül N; Kantar M; Ozkiliç H; Moretti JL
Nucl Med Commun; 1999 Nov; 20(11):991-1000. PubMed ID: 10572908
[TBL] [Abstract][Full Text] [Related]
6. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
9. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
10. Pinhole imaging of 131I-metaiodobenzylguanidine (131I-MIBG) in an animal model of neuroblastoma.
Accorsi R; Morowitz MJ; Charron M; Maris JM
Pediatr Radiol; 2003 Oct; 33(10):688-92. PubMed ID: 12908090
[TBL] [Abstract][Full Text] [Related]
11. Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.
Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1246-50. PubMed ID: 12811531
[TBL] [Abstract][Full Text] [Related]
12. Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells.
Meli ML; Carrel F; Waibel R; Amstutz H; Crompton N; Jaussi R; Moch H; Schubiger PA; Novak-Hofer I
Int J Cancer; 1999 Oct; 83(3):401-8. PubMed ID: 10495434
[TBL] [Abstract][Full Text] [Related]
13. Localization of 131I-labelled monoclonal antibody ERIC1 in a subcutaneous xenograft model of neuroblastoma in SCID mice.
Otto C; Jensen M; Dietlein M; Fischer T; Schmidt M; Tawadros S; Börner SM; Weber SA; Spitz R; Bloch W; Berthold F; Schicha H; Schomäcker K
Nucl Med Commun; 2006 Feb; 27(2):171-8. PubMed ID: 16404231
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunolocalization of neuroblastoma xenografts with chimeric antibody chCE7.
Novak-Hofer I; Amstutz HP; Haldemann A; Blaser K; Morgenthaler JJ; Bläuenstein P; Schubiger PA
J Nucl Med; 1992 Feb; 33(2):231-6. PubMed ID: 1732444
[TBL] [Abstract][Full Text] [Related]
15. 131I-MIBG in the diagnosis of primary and metastatic neuroblastoma.
El-Maghraby T
Gulf J Oncolog; 2007 Jul; (2):33-41. PubMed ID: 20084722
[TBL] [Abstract][Full Text] [Related]
16. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Conte M; Villavecchia GP; Garaventa A; Lanino E; De Bernardi B; Scopinaro G
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):21-4. PubMed ID: 9002744
[TBL] [Abstract][Full Text] [Related]
17. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
Gerretsen M; Schrijvers AH; van Walsum M; Braakhuis BJ; Quak JJ; Meijer CJ; Snow GB; van Dongen GA
Br J Cancer; 1992 Sep; 66(3):496-502. PubMed ID: 1520586
[TBL] [Abstract][Full Text] [Related]
19. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.
Taal BG; Hoefnagel C; Boot H; Valdés Olmos R; Rutgers M
Ann Oncol; 2000 Nov; 11(11):1437-43. PubMed ID: 11142484
[TBL] [Abstract][Full Text] [Related]
20. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response.
Reuland P; Geiger L; Thelen MH; Handgretinger R; Haase B; Müller-Schauenburg W; Niethammer D; Bares R
J Pediatr Hematol Oncol; 2001 Oct; 23(7):437-42. PubMed ID: 11878578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]